Phase 4 Gout Trial, Recruiting NCT06674109 Sponsor: Massachusetts General Hospital Condition: Gout
Back to Gout

Phase 4 Gout Trial, Recruiting

NCT06674109
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the study
  • You have been diagnosed with gout according to standard medical guidelines (confirm with trial site)
  • You have had at least one gout flare (painful gout attack) in the past 12 months
  • Your blood uric acid level is 6mg/dl or higher
  • You are male or female, aged between 18 and 80 years old
  • You are willing to follow the study procedures throughout the trial

Who may not be able to join:

  • Your kidneys are working at a very low level (below a certain threshold on a kidney function test) (confirm with trial site)
  • You are currently taking colchicine or anti-inflammatory painkillers (NSAIDs) to prevent gout attacks
  • You have an active heart or blood vessel condition, or type 1 diabetes
  • You are currently pregnant or breastfeeding
  • You have certain other health conditions, including a history of a dangerous blood sugar complication (ketoacidosis), severe liver disease, or active cancer (confirm with trial site)
  • You are currently taking weight-loss medications
  • You use a specific type of intensive insulin treatment involving multiple daily injections, or you take a type of water pill called a loop diuretic

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Hyon K Choi, MD, DrPH, Massachusetts General Hospital

Phone: 617-643-2140

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
28 May 2026
Est. completion
28 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Serum Urate Change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov